Can routine hemogram parameters be used asinflammatory biomarker in chronic obstructive pulmonarydisease exacerbations?

Aim: Confirming the diagnosis and identifying the etiology are critical for the management of chronic obstructive pulmonary disease (COPD) exacerbation. There is limited use of hemogram and C-reactive protein (CRP) in distinguishing infectious or non-infectious in exacerbations. However, procalcitonin is more precious in making this distinction, although it is less accessible and more expensive. The aim of this study was to investigate the association between procalcitonin, CRP, hemogram parameters and ratios, and the efficacy of new hematological ratios in differential diagnosis in subjects with COPD exacerbation.Materials and Methods: Subjects admitted to our outpatient clinic with the diagnosis of COPD were retrospectively analyzed and divided into 2 groups: those with acute exacerbation (n=52) and those are stable (n=64). Neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR) and platelet-lymphocyte ratio (PLR) were calculated for both groups. Subjects were grouped according to NLR cut-off point determined by the ROC curve (NLR

PDF

___

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017;195:557-82.
2. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
3. Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what? Clin Respir J 2012;6:208-14.
4. Sykes A, Mallia P, Johnston SL. Diagnosis of pathogens in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:642-6.
5. Vestbo J. Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2006;3:252-6.
6. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:426-35.
7. Karzai W, Oberhoffer M, Meier-Hellmann A, et al. Procalcitonin--a new indicator of the systemic response to severe infections. Infection 1997;25:329- 34.
8. Lee SJ, Lee HR, Lee TW, et al. Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. Korean J Intern Med 2016;31:891-8.
9. Kurtipek E, Bekci TT, Kesli R, et al. The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. J Pak Med Assoc 2015;65:1283-7.
10. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196- 204.
11. Peng C, Tian C, Zhang Y, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013;345:190-4.
12. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74.
13. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483.
14. Meisner M. Procalcitonin (PCT)-a new, innovative infection parameter. Biochemical and Clinical Aspects. 3. revised and expanded edition. New York: Thieme Stuttgart; 2000.
15. Chang C, Yao WZ, Chen YH, et al. [The changes and clinical implications of serum procalcitonin in acute exacerbations of chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 2006;29:444-7.
16. Nseir S, Cavestri B, Di Pompeo C, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008;76:253-60.
17. Zhang Y, Zhou L. [Diagnostic value of C-reactive protein and procalcitonin for bacterial infection in acute exacerbations of chronic obstructive pulmonary disease]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2014;39:939-43.
18. Ergan B, Sahin AA, Topeli A. Serum Procalcitonin as a Biomarker for the Prediction of Bacterial Exacerbation and Mortality in Severe COPD Exacerbations Requiring Mechanical Ventilation. Respiration 2016;91:316-24.
19. Gibson PH, Cuthbertson BH, Croal BL, et al. Usefulness of neutrophil/lymphocyte ratio as predictor of newonset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010;105:186-91.
20. Nunez J, Nunez E, Bodi V, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting longterm mortality in ST segment elevation myocardial infarction. Am J Cardiol 2008;101:747-52.
21. Sarraf KM, Belcher E, Raevsky E, et al. Neutrophil/ lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:425-8.
22. Taylan M, Demir M, Kaya H, et al. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients. Clin Respir J 2017;11:311-7.
23. In E, Kuluozturk M, Oner O, et al. The Importance of Neutrophil-to-Lymphocyte Ratio in Chronic Obstructive Pulmonary Disease. Turk Thorac J 2016;17:41-6.
24. Bilir B, Altıntaş N, Aydın M, et al. The Predictive Role of Neutrophil to Lymphocyte ratio in Chronic Obstructive Pulmonary Disease. 2016;13.
25. Farah R, Ibrahim R, Nassar M, et al. The neutrophil/ lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD. Panminerva Med 2017;59:203-9.
26. Furutate R, Ishii T, Motegi T, et al. The Neutrophil to Lymphocyte Ratio Is Related to Disease Severity and Exacerbation in Patients with Chronic Obstructive Pulmonary Disease. Intern Med 2016;55:223-9.
27. Yao C, Liu X, Tang Z. Prognostic role of neutrophillymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis 2017;12:2285-90.
28. van de Geijn GM, Denker S, Meuleman-van Waning V, et al. Evaluation of new laboratory tests to discriminate bacterial from nonbacterial chronic obstructive pulmonary disease exacerbations. Int J Lab Hematol 2016;38:616-28.
29. Tanriverdi H, Ornek T, Erboy F, et al. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr 2015;127:756-63.
30. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol 2020.